Aurobindo Pharma Ltd (AUROPHARMA) Q1FY26 Concall Summary - Jun-2025 Qtr
Performance Overview
- Aurobindo Pharma reported consolidated revenue growth of 4% YoY, reaching 7,868 crores, driven by European and growth market operations, along with the ARV segment.
- U.S. formulations base business demonstrated stability and resilience.
- EBITDA for the quarter was 1,603 crores with a margin of 20.4%. Excluding gRevlimid, EBITDA growth was 12% YoY.
- The Pen-G manufacturing plant resumed operations on July 1st, 2025, after receiving necessary clearances.
- The company maintains an optimistic outlook for sustained growth momentum, supported by volume expansion, product launches, and a stable pricing environment.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.